Bayer's Asundexian Math: A €3 Billion Peak Sales Bet Confronts a Stubborn Cash Drain
Published on 11/10/2026 at 20:31 | Editorial boerse-global.de
Bayer's investment case has migrated from the laboratory to the sales force. With US approval of its anticoagulant now in hand under the Sunharbo brand, the question for shareholders is no longer whether the drug works but how much revenue it can actually generate — and whether that money arrives fast enough to matter.
The stakes are elevated because the stock has already rallied 55% since the start of the year. Anyone weighing further upside now has to judge whether new medicines can offset the erosion of older ones. Asundexian is meant to help plug the gap left by expiring Xarelto patents and declining Eylea sales, and Bayer says the product will reach the market a year earlier than originally planned — a head start on revenue, provided the commercial rollout delivers.
Bank of America puts peak annual sales for Asundexian at roughly €3 billion. Consensus sits nearer €2 billion, while the most bullish case at the house envisions €7 billion. That spread is a measure of the commercial uncertainty: everything hinges on how many patients qualify and how widely the drug is actually used.
The label is narrow by design. Approval covers the combination with an antiplatelet agent following a mild-to-moderate non-cardioembolic ischemic stroke or a mini-stroke. Jefferies reckons Sunharbo suits about 40% of stroke patients and values the US and European market at around €2 billion. Reuters reports a US list price of about $748.50 per month. An attractive price point, in other words, set against a clearly bounded patient pool.
Efficacy Backs the Revenue Thesis
The clinical data give the commercial case something to stand on. In a trial of more than 12,000 patients, Asundexian combined with other anticoagulants cut the risk of a recurrent ischemic stroke by 26%.
Should investors sell immediately? Or is it worth buying Bayer?
A successful launch would carry extra weight because other new Bayer medicines are already growing. Nubeqa's revenue rose 58.3% in currency-adjusted terms to about €1 billion in the third quarter of 2026, and Kerendia expanded briskly as well — up 64.9%. Bank of America ties a strong Asundexian rollout to markedly better growth for the pharmaceuticals division, which it sees expanding at roughly 7% a year at its expected peak-sales level. That remains a modeling assumption, contingent on the commercial trajectory living up to the estimate.
Deutsche Bank, for its part, lifted its target price on Bayer to €65 from €60 today while reaffirming its buy rating. More telling than the target itself are the higher earnings forecasts behind it. Analyst Virginie Boucher-Ferte raised her 2026 adjusted EBITDA projection by about 3% to €10.060 billion, crediting the pharmaceuticals business while nudging Crop Science expectations lower. She also lifted her EBITDA and per-share earnings estimates for 2027 and 2028 by roughly 3% each, extending the more confident view beyond the current fiscal year.
The operating evidence is there. Third-quarter 2026 pharma EBITDA climbed 23.6%, with the margin reaching 27.6%.
Warnings and Red Ink Cap the Upside
The FDA flags a heightened risk of severe bleeding in patients over 75 and during the first 90 days of treatment, according to Reuters. Those caveats belong in any economic assessment because they shape patient selection. Jefferies analyst Michael Leuchten sees the risk to Bayer's pharmaceutical pipeline as substantially reduced by the approval, which arrived broadly as expected, yet he keeps a "Hold" rating — consistent with a cautious stance while the potential revenue contribution trails more optimistic forecasts.
At group level, the latest figures show room for improvement. Bayer posted a net loss of €672 million in the third quarter of 2026 and negative free cash flow of €293 million. Net financial debt stood at €31.1 billion at the end of September 2026, a figure that already reflects €3 billion in proceeds from the Apollo transaction. A weaker agricultural business adds to the drag, so a strong pharmaceutical product only durably improves the outlook if the group's overall financial trajectory improves alongside it.
The next real test may come from a rival. Bank of America expects data on Milvexian in stroke prevention as early as the fourth quarter of 2026, with results in atrial fibrillation anticipated in early 2027. How those readouts reshape Asundexian's competitive profile is what matters for Bayer shareholders. Fourth-quarter 2026 results are due on 24 February 2027, offering a further occasion to weigh pharmaceutical growth and the group's finances together.
For now, the optimistic valuation has an operating justification as long as pharma strength endures. The decisive proving ground, though, is cash generation: higher earnings estimates only earn Bayer more confidence when they translate into sturdier financing capacity.
Ad
Bayer Stock: New Analysis - 10 November
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
